RiboX Secures FDA IND Clearance for World's First Circular RNA-Based In Vivo CAR-T Therapy

RiboX received FDA IND clearance to begin Phase I clinical trials for RXIM002, the first circular RNA-based in vivo CAR-T therapy targeting autoimmune cytopenias using a targeted lipid nanoparticle delivery platform.

This Wire brief sits within Fusion42's coverage of Biotech.